Bortezomib-induced bronchiolitis obliterans organizing pneumonia
- PMID: 23133779
- PMCID: PMC3485493
- DOI: 10.1155/2012/430141
Bortezomib-induced bronchiolitis obliterans organizing pneumonia
Abstract
Introduction. Bortezomib is a proteasome inhibitor indicated for the treatment of multiple myeloma patients. The most frequent side effects are gastrointestinal and neurological. Serious pulmonary complications have been described rarely. Observation. This case involves a 74-year-old man suffering from IgG Kappa myeloma treated with bortezomib, melphalan, and dexamethasone. After administering chemotherapy, the patient developed an acute respiratory distress syndrome (ARDS). A surgical pulmonary biopsy proved the existence of bronchiolitis obliterans organizing pneumonia (BOOP) lesions. Systemic corticotherapy led to a rapid improvement in the patient's condition. Conclusion. This is the first reported histologically confirmed case of bortezomid-induced BOOP. Faced with severe respiratory symptoms in the absence of other etiologies, complications due to bortezomid treatment should be evoked and corticotherapy considered.
Figures




Similar articles
-
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.Oncol Lett. 2016 Mar;11(3):2255-2260. doi: 10.3892/ol.2016.4204. Epub 2016 Feb 8. Oncol Lett. 2016. PMID: 26998158 Free PMC article.
-
Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma.Saudi J Kidney Dis Transpl. 2019 Jul-Aug;30(4):974-977. doi: 10.4103/1319-2442.265477. Saudi J Kidney Dis Transpl. 2019. PMID: 31464258
-
Bronchiolitis interstitial pneumonitis: a pathologic study of 31 lung biopsies with features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis, with clinical correlation.Ann Diagn Pathol. 2008 Jun;12(3):171-80. doi: 10.1016/j.anndiagpath.2007.07.002. Epub 2007 Oct 24. Ann Diagn Pathol. 2008. PMID: 18486892
-
[Radiation-induced bronchiolitis obliterans with organizing pneumonia].Cancer Radiother. 2017 Apr;21(2):148-154. doi: 10.1016/j.canrad.2016.12.001. Epub 2017 Apr 14. Cancer Radiother. 2017. PMID: 28385367 Review. French.
-
[Bronchitis obliterans associated with bronchiolitis obliterans with organizing pneumonia in a child and literature review].Zhonghua Er Ke Za Zhi. 2016 Jul;54(7):523-6. doi: 10.3760/cma.j.issn.0578-1310.2016.07.010. Zhonghua Er Ke Za Zhi. 2016. PMID: 27412744 Review. Chinese.
Cited by
-
Bortezomib induced pulmonary toxicity: a case report and review of the literature.Am J Blood Res. 2020 Dec 15;10(6):407-415. eCollection 2020. Am J Blood Res. 2020. PMID: 33489450 Free PMC article.
-
Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review.Oncol Lett. 2016 Mar;11(3):2255-2260. doi: 10.3892/ol.2016.4204. Epub 2016 Feb 8. Oncol Lett. 2016. PMID: 26998158 Free PMC article.
-
Bortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature.Case Rep Med. 2018 Nov 25;2018:2913124. doi: 10.1155/2018/2913124. eCollection 2018. Case Rep Med. 2018. PMID: 30595697 Free PMC article.
References
-
- Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107(9):3492–3494. - PubMed
-
- Dun X, Yuan Z, Fu W, Zhang C, Hou J. Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematological Oncology. 2010;28(1):49–52. - PubMed
-
- Zappasodi P, Dore R, Castagnola C, et al. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. Journal of Clinical Oncology. 2007;25(22):3380–3381. - PubMed
-
- Boyer JE, Batra RB, Ascensao JL, Schechter GP. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood. 2006;108(3):p. 1113. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources